Clinical-stage biotech stocks carry significant risks, but also offer explosive upside potential. These companies are built ...

FDA starts review of Lantheus’ generic version of Novartis radiopharma drug Lutathera for GEP-NET tumours.

New drugs called antibody-drug conjugates help patients with cancers that used to be beyond treatment ...

CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder. Factor XIIa ...